Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics has received FDA clearance for physician sponsored investigative new drug (IND) application to begin Phase I trial of ICT-121.
Subscribe to our email newsletter
The trial will initially test the vaccine in up to 20 patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
ICT-121 is IMUC’s novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
IMUC president and CEO Manish Singh said, "Preclinical studies conducted by IMUC indicate that ICT-121 effectively targets CD-133, a protein that is over-expressed by a very wide range of solid tumors, including glioblastoma, pancreatic, breast, non-small-cell lung cancer, and several other malignancies associated with poor survival and limited treatment options."
The ICT-121 is the company’s second dendritic-cell-based vaccine to enter the clinic. Like ICT-107, ICT-121 targets the cancer stem cells (CSCs) that are believed to be the root cause of many cancers, according to IMUC.